PRIMARY DERMAL IRRITATION POTENTIAL OF COMPONENTS OF THE M-258A-ETC(U)

SEP 81 J T FRUIN, M A HANES
INSTITUTE REPORT NO. 101

PRIMARY DERMAL IRRITATION POTENTIAL OF COMPONENTS OF THE M-258A-1 DECONTAMINATION KIT (Study 1)

JOHN T. FRUIN, DVM, PhD, LTC VC
and
MARTHA A. HANES, DVM, CPT VC

TOXICOLOGY GROUP,
DIVISION OF RESEARCH SUPPORT

SEPTMBER 1981

Toxicology Series 6

LETTERMAN ARMY INSTITUTE OF RESEARCH  PRESIDIO OF SAN FRANCISCO  CALIFORNIA 94129
Toxicology Series 6

Reproduction of this document in whole or in part is prohibited except with the permission of the Commander, Letterman Army Institute of Research, Presidio of San Francisco, California 94129. However, the Defense Technical Information Center is authorized to reproduce the document for United States Government purposes.

Destroy this report when it is no longer needed. Do not return it to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

In conducting the research described in this report, the investigation adhered to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on Revision of the Guide for Laboratory Animal Facilities and Care, Institute of Laboratory Animal Resources, National Research Council.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-3)

(Signature and date)
**Primary Dermal Irritation Potential of Components of the M-258A-1 Decontamination Kit (Study 1).**

The dermal irritation potential of components of the Prototype M-258A-1 decontamination kit was assessed by using the modified Draize test. The test called for approximately 0.5 g of material to be held in contact with the skin of rabbits for 24 hr. Both components, Decon I and Decon II, when applied separately and together caused severe erythema and necrosis after 24 hr. Further testing of these components is recommended to determine if they present a significant hazard.
ABSTRACT

The dermal irritation potential of components of the Prototype M-258A-I decontamination kit was assessed by using the modified Draize test. The test called for approximately 0.5 g of material to be held in contact with the skin of rabbits for 24 hours. Both components, Decon I and Decon II, when applied separately and together caused severe erythema and necrosis after 24 hours. Further testing of these components is recommended to determine if they present a significant hazard.
PREFACE

Primary Dermal Irritation Report

TESTING FACILITY: Letterman Army Institute of Research
Presidio of San Francisco, CA 94129

SPONSOR: Letterman Army Institute of Research
Presidio of San Francisco, CA 94129

PROJECT: Medical Defense Against Chemical Agents 612772.875.

GLP STUDY NUMBER: 81011

STUDY DIRECTOR: LTC (P) John T. Fruin, DVM, PhD, VC, Diplomate of
American College of Veterinary Preventive Medicine

PRINCIPAL INVESTIGATOR: CPT Martha A. Hanes, DVM, VC

PATHOLOGY REPORTING: CPT George T. Makovec, DVM, VC
MAJ Glen E. Marrs Jr., DVM, MS, VC, Diplomate
of American College of Veterinary Pathologists.

RAW DATA: A copy of the final report, study protocol, raw data, and
standard operating procedures will be retained in the LAIR
Archives.

TEST SUBSTANCES:
A. Decon I consists of a pad pre-wetted with
hydroxyethane (ethanol) 72 ± 2%, phenol 10 ± 0.5%,
sodium hydroxide 5 ± 0.5%, ammonium hydroxide
0.2 ± 0.05% and water.

B. Decon II consists of a pad impregnated with a
quantity of crystalline chloramine B and an equal
quantity of liquid contained in breakable glass
ampoules covered with nylon mesh. The liquid con-
tains hydroxyethane (ethanol) 45 ± 2%, zinc
chloride 5±0.5% and water. Just before dosing,
the ampoules were broken and thus the chloramine B
impregnated pad was saturated with liquid.

C. Decon I and Decon II combined

D. Control (dry 1 inch square cotton gauze pad)

WORK UNIT: 302 Studies on Potential Dermal Irritation of M-258A-1 Kit

PURPOSE: The purpose of this study was to determine the primary dermal
irritation potential of the test substance listed above.
ACKNOWLEDGMENTS

The authors wish to thank LTC Kenneth Black MD, MC; SP5 Lance White; SP5 Leonard Sauers, BA; SP4 Thomas Kellner, BS; SP4 Larry Mullen, BS; PFC Evelyn Zimmerman; John Dacey; Carolyn Lewis, MS; for assistance in performing the research, and for advice in scoring the irritation reactions. The authors also wish to thank M. Mershon, VMD; LTC (P) E. Houston, PhD, MS; LTC R. Howarth, VMD, VC, of the U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Grounds, MD, for providing prototype M-258A-1 Decontamination Kits and background information.
Signatures of Principal Scientists Involved In The Study

We, the undersigned, believe the study, GLP study number 81011 described in this report to be scientifically sound and the results and interpretation to be valid. The study was conducted to comply, to the best of our ability, with the Good Laboratory Practice Regulations for Nonclinical Laboratory Studies outlined by the Food and Drug Administration.

MARSHA A. HANES, DVM / DATE  
MARTHA A. HANES, DVM / DATE
CPT, VC  
JOHN T. FRUIN, DVM, PhD / DATE
Principal Investigator  
LTC (F), VC  
Study Director
MEMORANDUM FOR RECORD

SUBJECT: Report of GLP Compliance

I hereby certify that LAIR GLP study 81011 was a Primary Dermal Irritation Test study run concurrently and co-located with study 81007. Study records for 81011 were inspected during the inspection of 81007 on:

11 May 81

Findings were reported to the Study Director on 15 May 1981. This inspection is also included in the July 1981 report to management.

JOHN C. JOHNSON
CPT, MS
Quality Assurance Officer
TABLE OF CONTENTS

Abstract.................................................................................................................i
Preface.....................................................................................................................iii
Acknowledgments....................................................................................................iv
Signatures of Principal Scientists..............................................................................v
Report of Quality Assurance Unit...........................................................................vi
Table of Contents.....................................................................................................vii

BODY OF REPORT

INTRODUCTION

Deviation from Standards.........................................................................................2
Objective of Study.......................................................................................................3

METHODS

Historical Listing of Study Events.............................................................................4
Animal Data...............................................................................................................4
Environmental Conditions.......................................................................................5
Dosing Levels............................................................................................................5
Dosing Procedures.....................................................................................................6

RESULTS

Scoring.......................................................................................................................6
Clinical Observations...............................................................................................8

DISCUSSION.............................................................................................................8
CONCLUSION...........................................................................................................9
RECOMMENDATION...............................................................................................9

vii
REFERENCES.................................................................10

APPENDICES

Appendix A Pathology Report.................................11

Appendix B Summary of Primary Skin Irritation Test Data.19

OFFICIAL DISTRIBUTION LIST........................................24
The urgent requirement for defensive measures and decontamination procedures was dramatically demonstrated to allied powers in the European Theater during World War I by the mass casualties resulting from the use of blister agents. Losses to the allies were high, because they lacked defensive capabilities. Probably more important they lacked sufficient offensive chemical warfare capabilities to deter the enemy from using chemical agents. The unclassified documentation of the use of antipersonnel chemical warfare agents since World War I has been difficult because the offensive use of chemical agents is a violation of treaties and creates negative world opinion. The clandestine use of offensive antipersonnel agents against guerrilla and poorly equipped forces has been reported in the popular press in recent years. The use of offensive chemical agents has also been suppressed because the major military powers possess chemical warfare capability and have not initiated chemical attacks for fear of similar retaliatory strikes. Current Eastern Block doctrine, although rarely if ever published or discussed publicly, is presumed to stress the use of munitions containing chemical agents integrated into conventional fire patterns (1). Thus there remains an urgent need for the United States and her allies to continue to pursue vigorously research and development efforts in the area of medical defense against chemical warfare agents. The rapid removal of chemical agents from the skin is an essential element in protecting personnel from chemical agents. The M-13 kit, a Fullers earth preparation, was developed before the M-258 kit as a means to remove chemical material by absorption (2,3). In addition to the physical removal of chemical agents, active chemical neutralization is desirable. Neutralization continues after protective gloves, mask and garments are in place. The M-258 decontamination kit, which is currently in the Army system, combines both physical removal and active chemical neutralization.

The original M-258 decontamination kit was type classified in the mid 1970s. It consisted of a plastic carrying case containing two plastic scrapers, a plastic container of Decon I solution, a plastic container of Decon II solution with a glass ampoule of chloramine B enclosed, and cotton gauze pads. The instructions contained on the plastic container directed the user to remove any suspected chemical agent with the plastic scrapers. The user was
instructed to open the Decon I container with the point of a nail, which has its head imbedded in the plastic container lid. He was then instructed to saturate one of the cotton gauze pads and wipe exposed and contaminated area for one minute. The user was then instructed to break the glass ampoule inside the Decon II, shake well, open Decon II with the nail, saturate another cotton gauze pad and wipe the same area for 2 to 3 minutes (2).

The difficulty soldiers had in using the kit correctly, the caustic and irritating action of the chemical components, the abrasive action of wiping a limited area with a gauze pad for 4 minutes, and the potential for abrasion by broken glass from the Decon II container, were serious shortcomings of the M-258 kit (4). Nevertheless, the benefit/risk evaluation of the kit was favorable, but the need for continued research development efforts was recognized (Letter from US Armament Research and Development Command, DADAR-CLW-E, to US Army Training and Doctrine Command, ATCD-CF-S, Subject: Product Improvement proposal for Decontamination Kit M-258, dated 17 November 1977). Modifications already developed have made the kit much easier to use, reduced risk due to abrasion by broken glass, and reduced abrasion risk from the materials used to wipe the exposed skin (Contract Report ARCSL-CR-79046 to US Army Armament Research and Development Command for Contract DAAKII-78-C-0025, Subject: Feasibility of personnel Decontamination Kit, dated December 1979). The modified kit M-258A-1 consists of the plastic containers with six flex pouches. Three of the flex pouches contain pads saturated with Decon I solution. The remaining three pouches each contain pads impregnated with Chloramine B, and breakable glass vials of Decon II solution inside a nylon mesh bag designed to contain glass particles (5).

Deviation from standards

Rather than applying liquid test substance on gauze, liquid impregnated pads from the M-258A-1 decontamination kit were cut into roughly one inch squares. Decon I squares weighed about 0.3 g each, Decon II squares weighed about 0.6 g each. For Decon I dosing, two squares were applied one on top of the other. For Decon II dosing, one square was applied. For Decon I plus Decon II a smaller square (0.5 to 0.7 in) Decon II pad was sandwiched between two Decon I pads of similar size. Using these dosing procedures, we anticipated an effective dose level of 0.5 g test substance per site.

Chemical analyses were not conducted except for measuring pH. The pH of Decon I was 10.7-10.8, Decon II was 6.5-6.6, and combined Decon I and II was 10.6-10.7. Chemical composition was considered to be that printed on the outer container for the prototype M-258A-1 decontamination kit (Tables 1 and 2). Compound stability and purity are unknown.
TABLE 1 (6)
CHEMICAL ANALYSIS OF DECON I
(pH = 10.7 - 10.8)

<table>
<thead>
<tr>
<th>Component</th>
<th>ETOH</th>
<th>H₂O</th>
<th>Phenol</th>
<th>NaOH</th>
<th>NH₄OH</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>72%±2%</td>
<td>q.s.</td>
<td>10±0.5%</td>
<td>5.0±0.5%</td>
<td>0.2±0.05%</td>
</tr>
<tr>
<td>Name</td>
<td>ethanol</td>
<td>water</td>
<td>phenol</td>
<td>sodium hydroxide</td>
<td>ammonium hydroxide</td>
</tr>
<tr>
<td>Molecular Structure</td>
<td>C₂H₆O</td>
<td>H₂O</td>
<td>C₆H₅O</td>
<td>NaOH</td>
<td>NH₄OH</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>46.07</td>
<td>18.016</td>
<td>94.12</td>
<td>40.01</td>
<td>35.36</td>
</tr>
</tbody>
</table>

TABLE 2 (6)
CHEMICAL ANALYSIS OF DECON II
(pH = 6.4 - 6.6)

<table>
<thead>
<tr>
<th>Component</th>
<th>*LIQUID PORTION</th>
<th>*SOLID PORTION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ETOH</td>
<td>H₂O</td>
</tr>
<tr>
<td>%</td>
<td>45±2%</td>
<td>50±2.5%</td>
</tr>
<tr>
<td>Name</td>
<td>ethanol</td>
<td>water</td>
</tr>
<tr>
<td>Molecular Structure</td>
<td>C₂H₆O</td>
<td>H₂O</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>46.07</td>
<td>18.016</td>
</tr>
</tbody>
</table>

* Equal quantities of liquid and solid are mixed to form Decon II.

Objective of Study

The objective of this study was to determine the primary dermal irritation potential of the components of the Prototype M-258A-1 decontamination kit.
METHODS

Historical Listing of Study Events

16 April 1981  Rabbits arrived, they were weighed, tattooed, sexed, and quarantined for two weeks.
23 April 1981  Animals were weighed.
30 April 1981  Animals were released from quarantine, close clipped, and marked.
1 May 1981    Animals were weighed, randomized into two specific groups and sites for exposure randomized.
4 May 1981    Animals were dosed according to SOP-OP-STX-34, except as stated in deviations from standards. Animals were observed daily, only significant or abnormal observations were recorded.
5 May 1981    Bandages were removed and the 24-hour score was taken. One animal was sacrificed for histopathology of exposure sites.
7 May 1981    Animals were weighed and the 72-hour score was taken. One animal was sacrificed for histopathology of exposure sites.
11 May 1981   The 7-day score was taken.
14 May 1981   The animals were weighed.
18 May 1981   The 14-day score was taken. Animals remained on study, as not all of irreversible damage had healed.
22 May 1981   A 18-day score was taken for animals still on study.
26 May 1981   A 22-day score was taken, all animals still on study were released.

Animal Data

Animal: New Zealand Rabbits
Sex: Male
Source: Elkhorn Rabbitry
Pre-test Conditioning:

A. Quarantine from 16 April 1981 to 30 April 1981.

B. Animals were close-clipped and test areas marked.


Number of Animals on test: 8 animals - each animal had 4 test sites and received each of the three test substances and a control patch.

Age of animals at start of study: young adults

Body Weight Range: 2.5 - 3.5 kg

Condition of animals at start of study: normal

Environmental Conditions

Caging: Number/cage = 1; Type cage used = stainless steel, wire mesh bottom, battery type, no bedding, automatic flushing.

Diet: Purina Certified Rabbit Chow #5322 approximately 110 g per day supplemented with about 45 g of fresh carrots.

Water: Central line to cage battery with automatic lick dispensers.

Temperature: 69 ± 5 F (21 ± 3 C)

Relative Humidity: about 60 ± 10%

Photoperiod: 0530 - 2000 hr/day (14 1/2 hr of light).

Dosing Levels

A. Approximately 0.5 g Decon I

B. Approximately 0.5 g Decon II

C. Approximately 0.25 g of Decon I and 0.25 g Decon II.

D. Control (nothing was applied)
Dosing Procedures

Method and frequency of administration were specified by Department of the Army (2) and Environmental Protection Agency (7). The backs of the animals were close-clipped and divided into quadrants designated I, II, III, and IV starting in the right shoulder area and proceeding clockwise. Areas I and IV were intact on all animals, and areas II and III were abraded by making two perpendicular scratches in the stratum corneum of the skin about 1 1/2 inch long by using an escarifier. The four application sites were about 10 cm apart. A standard latin square table was used to randomize the test sites (SOP-OP-STX-34).

The test substance impregnated pads were taped over the test sites. A plastic strip held on by elastic tape was placed around the animal to retard evaporation and to insure skin contact by the test substance. The test substance was in contact with the skin for 24 hours. At the end of the exposure period, the wrapping was removed, the skin wiped if material was adherent, and the areas were scored (8).

RESULTS

Scoring

Originally eight animals were exposed to the chemicals. Animals F8100025 and F8100017 were randomly chosen for histologic investigation of depth of damage at 24 and 72 hours, respectively. The pathology reports appear in Appendix A.

Seven animals were scored at 24 and 72 hr, 7,14,18, and 22 days for edema and erythema (Table 3). The primary skin irritation test data are summarized in Appendix B. Abraded (sites II and III) and intact areas (site I and IV) were graded separately as well as together. The scores obtained were used for a basis for categorization. Primary irritation potential values were calculated from the 24- and 72-hr scores.


**TABLE 3**

**EVALUATION OF SKIN REACTIONS (9)**

<table>
<thead>
<tr>
<th>Erythema and Eschar Formation</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No erythema</td>
<td>0</td>
</tr>
<tr>
<td>Very slight erythema (barely perceptible)</td>
<td>1</td>
</tr>
<tr>
<td>Well-defined erythema</td>
<td>2</td>
</tr>
<tr>
<td>Moderate-to-severe erythema</td>
<td>3</td>
</tr>
<tr>
<td>Severe erythema (beet redness) to slight eschar formation</td>
<td>4</td>
</tr>
<tr>
<td>(injurious in depth)</td>
<td></td>
</tr>
<tr>
<td>Possible total erythema score</td>
<td>4*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Edema Formation</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No edema</td>
<td>0</td>
</tr>
<tr>
<td>Very slight edema (barely perceptible)</td>
<td>1</td>
</tr>
<tr>
<td>Slight edema (edges of area well defined by definite raising)</td>
<td>2</td>
</tr>
<tr>
<td>Moderate edema (edges raised approximately 1 mm)</td>
<td>3</td>
</tr>
<tr>
<td>Severe edema (raised more than 1 mm and extending beyond area of</td>
<td>4</td>
</tr>
<tr>
<td>exposure)</td>
<td></td>
</tr>
<tr>
<td>Possible total edema score</td>
<td>4*</td>
</tr>
</tbody>
</table>

Possible total score for primary irritation                        | 8     |

*Any skin reaction more serious than severe edema, vesiculation, ulceration, or necrosis places the chemical in Category IV.

Compounds producing combined averages (intact and abraded scores) of 2 or less are considered mildly irritating (Category I), whereas those with indexes from 2 to 5 are moderate irritants (Categories II and III).

Category IV irritants are compounds producing moderate to severe primary irritation of intact skin and skin surrounding an abrasion. In addition these compounds produce necrosis, vesiculation, ulceration and/or eschars. (Category assignment and interpretation, personnel communication, AH McCleesh, 1980.)
Table 4 demonstrates the primary irritation indexes for the exposed areas.

TABLE 4

PRIMARY DERMAL IRRITATION INDEX FOR M-258A-1 DECONTAMINATION KITS

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Intact Score</th>
<th>Abraded Score</th>
<th>Combined Score</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decon I</td>
<td>5.7</td>
<td>7.5</td>
<td>6.7</td>
<td>IV</td>
</tr>
<tr>
<td>Decon II</td>
<td>7.8</td>
<td>7.4</td>
<td>7.6</td>
<td>IV</td>
</tr>
<tr>
<td>Decon I+II</td>
<td>5.6</td>
<td>5.8</td>
<td>5.7</td>
<td>IV</td>
</tr>
<tr>
<td>Control</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>I</td>
</tr>
</tbody>
</table>

Clinical Observations

When we removed the bandages, we observed wet burns (Decon I) or dry black areas (Decon II) of burned skin under the entire areas of application. The combined sites of Decon I and II were lightly tinted blue-green at the fringes by the zinc-ammonia complex.

Animals exposed to test substances were anorexic and were extremely sensitive over the exposed areas. All animals exhibited scarring after loss of the scabs, which occurred by post-exposure day 18. Animals were restrained by hand for application of test substance and were not kept in restrainers for the initial period. The animals did not damage bandages or selfmutilate during the course of the study. Two animals exhibited post-exposure secondary infection on application sites. The infected animals were not treated. The infected sites appeared to clear in 3 to 4 days.

DISCUSSION

Decon I and Decon II showed severe irritation potential.

Reports that solutions of Decon I and Decon II when combined...
neutralized each other were not confirmed by this study. They yielded slightly lower combined and abraded scores for these sites. From the clinical point of view, the lower scores for Decon I+II combined are purely academic. Severe damage and burning was produced by the Decontamination Kit constituents.

The interpretation for Category IV is that the compound should be resubmitted "in the form and the intended use concentrations" so that irritation potential can be reevaluated.

CONCLUSION

The prototype M-258A-1 kit contains potentially severe irritants.

RECOMMENDATIONS

It is recommended that the following studies be conducted to demonstrate the irritation potential of the chemicals when used as directed, or as they would be utilized in the field.

Six tests are suggested:

Tests 1 and 2 would include studies where the kit constituents would be used as directed on the plastic container; Tests 3 and 4 would include studies where freshly prepared chemicals contained in the kit would be applied in amounts needed to wet 1-inch square of rabbit skin; Tests 5 and 6 would include studies where physiological saline would be used to wipe the skin of rabbits for 1, 3, and 4 minutes to simulate the directed use of the M-258A-1 Kit. Each pair of tests would include occluded test sites (Tests 1, 3, 5) and non-occluded test sites (Tests 2, 4, 6).

Occluded is intended to mean the use of a plastic wrap and adhesive to retard evaporation and assure juxtaposition of the chemical and skin. Non-occluded means the total absence of tape, gauze and any wrapping materials.
REFERENCES


7. ENVIRONMENTAL PROTECTION AGENCY. Proposed health effects test standard for toxic substance control act test rules and proposed good laboratory practice standards for health effects. 40CPR part 772, Federal Register 44:44053-44093. Washington, DC, 1979

8. DRAIZE, J., H.Z. WOODARD, and H.O. CALVERY. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 83:377-390, 1944

Pathology Reports

<table>
<thead>
<tr>
<th>Appendix A-1</th>
<th>LAIR 30524</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix A-2</td>
<td>LAIR 30527</td>
<td>15</td>
</tr>
</tbody>
</table>

APPENDIX A
APPENDIX A-I
LAIR 30524

A. Rabbit, New Zealand White, male, 2 months.
B. ID: F8100025.
C. Dr. Hanes, TL10, Decontamination - CLP #81011.

D. History: This animal was exposed to skin decontamination solutions from the M-258A-l Decontamination kit. The dorsal thorax and lumbar areas were shaved and the solutions applied as follows:

- Quadrant I - Decon II, normal skin (slide 1).
- Quadrant II - Decon I & II, abraded skin (slide 2).
- Quadrant III - Control, abraded skin (slide 3).
- Quadrant IV - Decon I, normal skin (slide 4).

After 24 hours exposure time the rabbit was anesthetized with sodium pentobarbital, then exsanguinated by cutting the axillary arteries. Skin sections were harvested from each quadrant and fixed in 10% buffered neutral formalin. The skin sections were submitted to Pathology Services for histopathologic examination.

E. Gross findings: See history.

F. Morphologic findings:

Slide 1 - Skin: The skin overlying a narrow band of cutaneous muscle is almost devoid of epidermis. The surface is covered by a thin layer of flaking, fragmenting basophilic material with a few underlying remnants of epidermis at each end. Most of the epidermis is comprised of small cells with dense, eosinophilic cytoplasm and pyknotic or fragmenting nuclei. Several inflammatory cell foci, primarily heterophils with cell debris, underlie the epidermis or basophilic covering material. The entire epidermis is expanded and hypercellar with wide separation of collagen bundles. All structures in the upper 20% of the dermis including adnexia, are deeply eosinophilic and smudgy or granular. All the nuclei are pyknotic or fragmented. The eosinophilic zone is bounded by a prominent band of degenerating heterophils and debris. The irregularly straining and occasionally fragmenting collagen bands in the remaining dermis are widely separated and contain a prominent diffuse inflammatory cell infiltrate that is primarily heterophils with some lymphocytes, plasma cells and large mononuclear cells. There
are many variable sized irregularly shaped foci of lacy eosinophilic fibrillar material that often contains some free blood and are occasionally associated with small fragmenting vessels distributed throughout the dermis. Many of the spindle shaped cells throughout the dermis are rounded and occasionally have pyknotic nuclei.

DX: Necrosis, acute, diffuse, severe, epidermis, skin, rabbit.

DX: Degeneration acute, diffuse, dermis, skin.

Slide 2 - Skin: Essentially the same as slide 1 but the prominent band of inflammatory cell infiltrate is in the deep dermis, adjacent to but not involving the cutaneous muscle.

DX: Necrosis, acute, diffuse, severe, epidermis, skin.

DX: Degeneration, acute, diffuse, severe, dermis, skin.

Slide 3 - Skin: No lesions recognized (NLR), epidermis and dermis, skin.

Slide 4 - Skin: Essentially the same as slide 2.

DX: Necrosis, acute, diffuse, severe, epidermis, skin.

DX: Degeneration, acute, diffuse, severe, dermis, skin.

G. Morphologic diagnoses:

1. Necrosis, acute, diffuse, severe, epidermis, skin, rabbit - Decon I, Decon I & II, Decon II.

2. Degeneration, acute, diffuse, severe, dermis, skin - Decon I, Decon I & II, Decon II.

3. no recognized lesions, skin - Control.

H. Syndrome diagnosis: N/A.

I. Comment: The damage to the epidermis and upper dermis caused by Decon I, Decon I & II, and Decon II is probably due to direct caustic effect of the substances at high concentrations. The more subtle, but
still severe, effect in deeper dermis of skin sections exposed to Decon I, Decon I & II, and Decon II is probably a combination of direct toxic damage and hypoxia associated with vascular damage.

GEORGE T. MAKOVEC, DVM
CPT, VC
Pathology Services Group
Division of Research Support

GLEN E. MARRS, JR., DVM, MS
Diplomate of ACVP
MAJ, VC
Pathology Services Group
Division of Research Support
A. Animal Data: Rabbit, New Zealand White, male.
B. ID: F8100017.
C. Contributor: Dr. Hanes, TL10, GLP #81011.
D. History: This animal was exposed to skin decontamination solutions from the M-258A-1 Decontamination kit. The dorsal thorax and lumbar areas were shaved and the solutions applied as follows:

- Quadrant I - Decon I & II, normal skin (slide 1).
- Quadrant II - Control, abraded skin (slide 2).
- Quadrant III - Decon I, abraded skin (slide 3).
- Quadrant IV - Decon II, normal skin (slide 4).

After 72 hours exposure time the rabbit was anesthetized with sodium pentobarbital, then exsanguinated by cutting the axillary arteries. Skin sections were harvested from each quadrant and fixed in 10% buffered neutral formalin. The skin sections were submitted to Pathology Services for histopathologic examination.

E. Gross findings: See history.
F. Morphologic findings:

Slide 1 - Skin: The skin is covered by a heavily keratinized epithelium that is intact except for two small foci in which the remaining epithelial cells have dense eosinophilic cytoplasm and pyknotic nuclei. These foci contain a prominent inflammatory cell infiltrate, primarily heterophils, and cellular debris. In the upper 15% of the dermis, even under the intact epidermis, the collagen bundles are lightly eosinophilic, fragmented and granular. This portion of the dermis contains a moderate inflammatory cell infiltrate, comprised primarily of heterophils, with a few lymphocytes, plasma cells and mononuclear cells. Pavementing by heterophils is observed in a few small vessels within the altered area. There are a few small aggregates of lymphocytes and plasma cells with an occasional heterophil in the connective tissue sheaths of a few hair follicles deep in the dermis.

DX: Necrosis, acute, focal, severe, epidermis, skin, rabbit.
DX: Degeneration, acute, diffuse, mild to moderate, dermis, skin.

DX: Folliculitis, subacute, multifocal, minimal, hair follicles, skin.

Slide 2 - Skin: There are a few small aggregates of plasma cells and lymphocytes with an occasional heterophil in the connective tissue sheaths of a few hair follicles deep in the dermis.

DX: Folliculitis, subacute, multifocal, minimal, hair follicles, skin.

Slide 3 - Skin: Essentially the same as slide 1, but the epidermis is intact.

DX: Degeneration, acute, diffuse, mild to moderate, dermis, skin.

DX: Folliculitis, subacute, multifocal, minimal, hair follicles, skin.

Slide 4 - Skin: The entire skin surface is covered by a thick layer of densely eosinophilic material containing much cell debris. This material is almost completely separated from the dermis by a thin layer of epidermis. The epidermis is generally only one or two cells thick except in follicular areas where the epithelium piles and an occasional mitotic figure is present. The dermis adjacent to the epidermis contains a small amount of granular debris and inflammatory cell infiltrate that is comprised primarily of large mononuclear cells with granular cytoplasm and an occasional heterophil, lymphocyte or plasma cell. There are a few small aggregates of plasma cells and lymphocytes with an occasional heterophil in the connective tissue sheaths of a few hair follicles deep in the dermis.

DX: Hyperplasia, diffuse, moderate, epidermis, skin.

DX: Degeneration, subacute, diffuse, minimal to mild, dermis, skin.

DX: Folliculitis, subacute, multifocal, minimal, hair follicles, skin.

G. Morphologic diagnoses:

1. Necrosis, acute, diffuse, severe, epidermis, skin - Decon I & II.

2. Hyperplasia, diffuse, moderate, epidermis, skin - Decon I.

3. Degeneration, acute to subacute, diffuse, mild to moderate, dermis, skin - Decon I, Decon I & II.
4. Degeneration, subacute, diffuse, minimal to mild, dermis, skin - Decon II.

5. Folliculitis, subacute, multifocal, minimal, hair follicles, skin Decon I & II, Decon I, Decon II, control.

H. Syndrome diagnosis: N/A.

I. Comment: The damage to the epidermis and upper dermis caused by Decon I, Decon I & II, and Decon II is probably due to both direct and indirect toxic effect of the substances tested. The regeneration of the epithelium beneath the thick layer of debris on the skin exposed to Decon II suggests that the necrotic surface material may serve as a protective barrier. The minimal folliculitis in all the skin sections is considered to be an incidental finding and not related to exposure to the compounds tested.

GEORGE T. MAKOVEC, DVM
CPT, VC
Pathology Services Group
Division of Research Support

GLEN E. MARRS, JR., DVM, MS
Diplomate of ACVP
MAJ, VC
Pathology Services Group
Division of Research Support
Summary of Primary Skin Irritation Test Data

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-1</td>
<td>M-258A-1, Decon I</td>
<td>20</td>
</tr>
<tr>
<td>B-2</td>
<td>M-258A-1, Decon II</td>
<td>21</td>
</tr>
<tr>
<td>B-3</td>
<td>M-258A-1, Decon I and II</td>
<td>22</td>
</tr>
<tr>
<td>B-4</td>
<td>M-258A-1, Control</td>
<td>23</td>
</tr>
</tbody>
</table>

APPENDIX B
## APPENDIX B-I

### Summary of Primary Skin Irritation Test Data

<table>
<thead>
<tr>
<th>GLP Study No.</th>
<th>81011</th>
<th>Chemical Name</th>
<th>Conc.</th>
<th>Solvent</th>
<th>Decon</th>
<th>Filled</th>
<th>Applied</th>
<th>Conc.</th>
<th>Solvent</th>
<th>Decon</th>
<th>Filled</th>
<th>Applied</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Application</td>
<td>4 May 1981</td>
<td>*</td>
<td>NA</td>
<td>0.5</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>CPT HANES</td>
<td>2 layers of 1&quot; square section of towelett.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Irritation Scores

<table>
<thead>
<tr>
<th>Rabbit No.</th>
<th>Site</th>
<th>Erythema 24 hr</th>
<th>Edema 24 hr</th>
<th>Site</th>
<th>Erythema 24 hr</th>
<th>Edema 24 hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>F8100015</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>F8100016</td>
<td>IV</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>F8100017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F8100022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F8100023</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>F8100025</td>
<td>IV</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>F8100026</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F8100032</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total:</td>
<td></td>
<td>20</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Intact Score** = $\frac{1}{2} \times \text{No. of Sites on test}$

**Abladed Score** = $\frac{1}{2} \times \text{No. of Sites on test}$

**Primary Skin Irritation Index** = Category IV

Remarks: *F8100025 was randomly chosen for sacrifice at 24 hr for histological study.

*F810017 was chosen randomly for sacrifice at 72 hr for histological study.*

---

20
### Summary of Primary Skin Irritation Test Data

**GLP Study No.**: 81011  
**Chemical Name**:  
**Conc 'Solvent Ant Applied' Code**: M-250A-1  
**Date of Application**: 4 May 1981  
**Decom**: 11  
**Solvent**: NA  
**Amt Applied**: 0.5 g  
**Code**: B

**Principal Investigator**: CPT HANES  
* 1 layer of 1x1" section of towelette.

#### Irritation Scores

<table>
<thead>
<tr>
<th>Rabbit No.</th>
<th>Site</th>
<th>Erythema 24 hr</th>
<th>Edema 24 hr</th>
<th>Site</th>
<th>Erythema 24 hr</th>
<th>Edema 24 hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>F8100015</td>
<td></td>
<td></td>
<td></td>
<td>I</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>F8100016</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>F8100017</td>
<td>IV</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>F8100022</td>
<td></td>
<td></td>
<td></td>
<td>I1</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>F8100023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>F8100025</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F8100026</td>
<td>IV</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F8100032</td>
<td></td>
<td></td>
<td></td>
<td>I1</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

**Total**:  

- Intact Score: \( \frac{12}{2 \times \text{No. of Sites on test}} = \frac{47}{2 \times 2} = 7.8 \)
- Abruaded Score: \( \frac{12}{2 \times \text{No. of Sites on test}} = \frac{59}{2 \times 2} = 7.4 \)
- Total Score: \( \frac{2 \times \text{No. of Sites on test}} (47+59)/(2 \times 2) = 7.6 \)

**Primary Skin Irritation Index**: Category IV

**Remarks**:  
- *F8100025 was chosen randomly for histological section after 24 hr.
- *F8100017 was chosen randomly for histological section after 72 hr.

---

Note: The table and calculations are based on the provided data and the specified methodology.
APPENDIX B-3
Summary of Primary Skin Irritation Test Data

GLP Study No. 31011  Chemical Name | Conc. % | Column |amt applied | Site
--- | --- | --- | --- | ---
M-258A-1  |  | Decon 1 & 11 | *  | NA | x0.5 g | 1 C
Date of Application: 4 May 1981
Principal Investigator: CPT HANES  *1/2" x 1" of Decon 11 and 1x1" of Decon 1

Irritation Scores

<table>
<thead>
<tr>
<th>Rabbit No.</th>
<th>Site</th>
<th>Intact Skin Sites</th>
<th>Abraded Skin Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Erythema 24 hr 72 hr</td>
<td>Edema 24 hr 72 hr</td>
<td>Erythema 24 hr 72 hr</td>
</tr>
<tr>
<td>FB100015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100016</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB1C017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100023</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100025</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100026</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100025</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100026</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FB100022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>a</td>
<td>2</td>
<td>b</td>
</tr>
<tr>
<td></td>
<td>a+b</td>
<td>18</td>
<td></td>
</tr>
</tbody>
</table>

Intact Score = C/2 x No. of Sites on test

\[ \frac{45}{2(14)} = 5.6 \]

Abraded Score = C/2 x No. of Sites on test

\[ \frac{35}{2(12)} = 5.8 \]

Total Score = C/2 x No. of Sites on test

\[ \frac{(45+35)}{2(17)} = 5.7 \]

Primary Skin Irritation Index = Category IV

Remarks: *FB100025 was chosen randomly for histological section after 24 hr.
FB100017 was chosen randomly for histological section after 72 hr.

22
### APPENDIX B-4

Summary of Primary Skin Irritation Test Data

<table>
<thead>
<tr>
<th>GLP Study No.</th>
<th>Chemical Name</th>
<th>Conc</th>
<th>Solvent</th>
<th>Amt Applied</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>81011</td>
<td>M-250RA-1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>1 D</td>
</tr>
</tbody>
</table>

Date of Application: 4 May 1981
Principal Investigator: CPT HANES

#### Irritation Scores

<table>
<thead>
<tr>
<th>Rabbit No.</th>
<th>Site</th>
<th>Erythema 24 hr</th>
<th>72 hr</th>
<th>Edema 24 hr</th>
<th>72 hr</th>
<th>Site</th>
<th>Erythema 24 hr</th>
<th>72 hr</th>
<th>Edema 24 hr</th>
<th>72 hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>F8100015</td>
<td>IV</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100016</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100017</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100022</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100023</td>
<td>IV</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100025</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100026</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F8100032</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>I</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Intact Score = $c_1/2 \times \text{No. of Sites on test}$

Abrasied Score = $c_1^a/2 \times \text{No. of Sites on test}$

Total Score = $2 \times \text{No. of Sites on test}$

Primary Skin Irritation Index: Category I

Remarks: F8100025 was chosen randomly for histological section at 24 hr.

F8100017 was chosen randomly for histological section at 72 hr after.
OFFICIAL DISTRIBUTION LIST

Comander
US Army Medical Research and Development Command
ATTN: SGRD-S/ Mrs. Madigan
Fort Detrick, Frederick MD 21701

Defense Technical Information Center
ATTN: DTIC-DDA (12 copies)
Cameron Station
Alexandria VA 22314

Director of Defense Research and Engineering
ATTN: Assistant Director, Environmental and Life Sciences
Washington DC 20301

The Surgeon General
ATTN: DASG-TLO
Washington DC 20314

HQ DA (DASG-ZXA)
WASH DC 20310

Superintendent
Academy of Health Sciences
ATTN: AHIS-COM
Fort Sam Houston TX 78234

Assistant Dean
Institute and Research Support
Uniformed Services University of Health Sciences
917 Arlington Road
Bethesda MD 20014

Commander
US Army Environmental Hygiene Agency
Aberdeen Proving Ground MD 21070

US Army Research Office
ATTN: Chemical and Biological Sciences Division
P.O. Box 1232
Research Triangle Park NC 27709

Biological Sciences Division
Office of Naval Research
Arlington VA 22217

Director of Life Sciences
USAF Office of Scientific Research (AFSC)
Robins AFB
Washington DC 20332

Director
Walter Reed Army Institute of Research
Washington DC 20012

Commander
US Army Medical Research Institute of Infectious Diseases
Fort Detrick, Frederick MD 21701

Commander
US Army Research Institute of Environmental Medicine
Natick MA 01760

Commander
US Army Institute of Surgical Research
Brooke Army Medical Center
Fort Sam Houston TX 78234

Commander
US Army Institute of Dental Research
Washington DC 20012

Commander
US Army Medical Bioengineering
Research and Development Laboratory
Fort Detrick, Frederick MD 21701

Commander
US Army Aeromedical Research Laboratory
Fort Rucker AL 36362

Commander
US Army Biomedical Laboratory
Aberdeen Proving Ground
Edgewood Arsenal MD 21010

Commander
Naval Medical Research Institute
National Naval Medical Center
Bethesda MD 20014

Commander
USAF School of Aerospace Medicine
Aerospace Medical Division
Brooks Air Force Base TX 78235
DATE

ILME